Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Palisade Bio, Inc. (PALI : NSDQ)

• Company Description    Palisade Bio Inc. is a late-stage biopharma company advancing therapies which help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio Inc., formerly known as Seneca Biopharma Inc., is based in CARLSBAD, Calif. Number of Employees: 8

• Price / Volume Information    Yesterday's Closing Price: $2.35 Daily Weekly Monthly 20 Day Moving Average: 5,202,299 shares Shares Outstanding: 149.00 (millions) Market Capitalization: $350.16 (millions) Beta: 1.43 52 Week High: $2.64 52 Week Low: $0.53 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 30.56% 30.78% 12 Week 11.90% 10.10% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 7750 El Camino Real Suite 2A - Carlsbad,CA 92009 USA ph: 858-704-4900 fax: - pali@jtcir.com http://www.palisadebio.com

• General Corporate Information    Officers J.D. Finley - Chief Executive Officer; Chief Financial Officer; Donald A. Williams - Chairman Binxian Wei - Director Margery Fischbein - Director Robert J. Trenschel - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 696389402 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/23/26 Share - Related Items Shares Outstanding: 149.00 Most Recent Split Date: 4.00 (0.07:1) Beta: 1.43 Market Capitalization: $350.16 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.05 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.26 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/23/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 97.37 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 83.62% vs. Previous Quarter: 34.48% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - -240.81 06/30/25 - -214.94 ROA 12/31/25 - - 09/30/25 - -137.28 06/30/25 - -135.09 Current Ratio 12/31/25 - - 09/30/25 - 1.96 06/30/25 - 1.62 Quick Ratio 12/31/25 - - 09/30/25 - 1.96 06/30/25 - 1.62 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - - 09/30/25 - 0.02 06/30/25 - 0.44 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©